Profiel
Donald Mitchell worked as an Executive Director of Corporate Development at Idenix Pharmaceuticals LLC from 2005 to 2008.
He then served as a Consultant at F-Star Therapeutics, Inc. from 2008 to 2011.
Prior to his roles in the private sector, he worked as a Communications Officer and Assistant Engineer at the US Department of the Navy.
Mr. Mitchell completed his undergraduate studies at the United States Naval Academy and earned an MBA from the University of Virginia Darden School of Business.
Eerdere bekende functies van Donald Mitchell
| Bedrijven | Functie | Einde |
|---|---|---|
| IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | 01-01-2008 |
| US Department of the Navy (District of Columbia) | Public Communications Contact | - |
| SPRING BANK PHARMACEUTICALS, INC. | Operationeel Directeur | - |
Opleiding van Donald Mitchell
| United States Naval Academy | Undergraduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
F-Star Therapeutics, Inc. (United States)
 F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
| US Department of the Navy (District of Columbia) | Government |
